🚀 VC round data is live in beta, check it out!
Connect Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Connect Biopharma and similar public comparables like Tetratherix, Abionyx Pharma, Spero Therapeutics, Mayne Pharma Group and more.
Connect Biopharma Overview
About Connect Biopharma
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
Founded
2015
HQ
Employees
62
Website
Sectors
Financials (LTM)
EV
$84M
Connect Biopharma Financials
Connect Biopharma reported last 12-month revenue of $2M.
In the same LTM period, Connect Biopharma generated $2M in gross profit and had net loss of ($58M).
Revenue (LTM)
Connect Biopharma P&L
In the most recent fiscal year, Connect Biopharma reported revenue of $26M and EBITDA of ($22M).
Connect Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $26M | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($22M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (84%) | XXX | XXX | XXX |
| EBIT Margin | (3379%) | XXX | (82%) | XXX | XXX | XXX |
| Net Profit | ($58M) | XXX | ($16M) | XXX | XXX | XXX |
| Net Margin | (3248%) | XXX | (60%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Connect Biopharma Stock Performance
Connect Biopharma has current market cap of $138M, and enterprise value of $84M.
Market Cap Evolution
Connect Biopharma's stock price is $2.47.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $84M | $138M | 0.0% | XXX | XXX | XXX | $-0.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialConnect Biopharma Valuation Multiples
Connect Biopharma trades at 46.8x EV/Revenue multiple, and (3.9x) EV/EBITDA.
EV / Revenue (LTM)
Connect Biopharma Financial Valuation Multiples
As of March 25, 2026, Connect Biopharma has market cap of $138M and EV of $84M.
Equity research analysts estimate Connect Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Connect Biopharma has a P/E ratio of (2.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $138M | XXX | $138M | XXX | XXX | XXX |
| EV (current) | $84M | XXX | $84M | XXX | XXX | XXX |
| EV/Revenue | 46.8x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.9x) | XXX | XXX | XXX |
| EV/EBIT | (1.4x) | XXX | (4.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 46.8x | XXX | — | XXX | XXX | XXX |
| P/E | (2.4x) | XXX | (8.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Connect Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Connect Biopharma Margins & Growth Rates
Connect Biopharma's revenue in the last 12 month grew by 488%.
Connect Biopharma's revenue per employee in the last FY averaged $0.0M.
Connect Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 488% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (84%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (63%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1228% | XXX | 74% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2201% | XXX | 112% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 186% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Connect Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tetratherix | XXX | XXX | XXX | XXX | XXX | XXX |
| Abionyx Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Spero Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mayne Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Adagene | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Connect Biopharma M&A Activity
Connect Biopharma acquired XXX companies to date.
Last acquisition by Connect Biopharma was on XXXXXXXX, XXXXX. Connect Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Connect Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialConnect Biopharma Investment Activity
Connect Biopharma invested in XXX companies to date.
Connect Biopharma made its latest investment on XXXXXXXX, XXXXX. Connect Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Connect Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Connect Biopharma
| When was Connect Biopharma founded? | Connect Biopharma was founded in 2015. |
| Where is Connect Biopharma headquartered? | Connect Biopharma is headquartered in United States. |
| How many employees does Connect Biopharma have? | As of today, Connect Biopharma has over 62 employees. |
| Who is the CEO of Connect Biopharma? | Connect Biopharma's CEO is Barry D. Quart. |
| Is Connect Biopharma publicly listed? | Yes, Connect Biopharma is a public company listed on Nasdaq. |
| What is the stock symbol of Connect Biopharma? | Connect Biopharma trades under CNTB ticker. |
| When did Connect Biopharma go public? | Connect Biopharma went public in 2025. |
| Who are competitors of Connect Biopharma? | Connect Biopharma main competitors are Tetratherix, Abionyx Pharma, Spero Therapeutics, Mayne Pharma Group. |
| What is the current market cap of Connect Biopharma? | Connect Biopharma's current market cap is $138M. |
| What is the current revenue of Connect Biopharma? | Connect Biopharma's last 12 months revenue is $2M. |
| What is the current revenue growth of Connect Biopharma? | Connect Biopharma revenue growth (NTM/LTM) is 488%. |
| What is the current EV/Revenue multiple of Connect Biopharma? | Current revenue multiple of Connect Biopharma is 46.8x. |
| Is Connect Biopharma profitable? | No, Connect Biopharma is not profitable. |
| What is the current net income of Connect Biopharma? | Connect Biopharma's last 12 months net income is ($58M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.